The Role of Glucocorticoids in Hepatic Gluconeogenesis, Associated Pathologies, and Novel Therapeutic Approaches

Read full text Summarise with VIRAT
Authors: Yusuf Anıl Ay, Elif Çadırcı
Cited by: 0
References: 1

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Glucocorticoids are essential steroid hormones that play a pivotal role in regulating hepatic gluconeogenesis, thereby contributing to the maintenance of systemic glucose homeostasis. This review provides a comprehensive overview of the molecular mechanisms by which glucocorticoids modulate hepatic glucose production and explores their clinical implications in metabolic health and disease. Glucocorticoids exert their primary effects through genomic pathways, involving the translocation of activated glucocorticoid receptors (GRs) into the nucleus, where they bind to glucocorticoid response elements (GREs) on DNA. This interaction promotes the transcription of key gluconeogenic enzymes, notably phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Additionally, glucocorticoids enhance the expression of these enzymes by synergizing with critical transcriptional regulators such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), forkhead box protein O1 (FOXO1), and hepatocyte nuclear factor 4-alpha (HNF-4α). Beyond their hepatic effects, glucocorticoids influence systemic metabolism by stimulating proteolysis and lipolysis in peripheral tissues, thereby increasing the availability of substrates for gluconeogenesis. Furthermore, they antagonize insulin signaling, contributing to insulin resistance. The local activation of glucocorticoids via the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) adds another layer of regulation. Non-genomic effects through the cAMP/PKA/CREB signaling pathway allow for rapid metabolic responses. Chronic glucocorticoid excess, as observed in conditions like Cushing’s syndrome, is linked to the development of type 2 diabetes. Emerging therapeutic strategies, including 11β-HSD1 inhibitors, selective GR modulators, and targeted inhibitors of gluconeogenic enzymes, present promising avenues for managing glucocorticoid-induced metabolic disorders.

Fields of Study & Subjects

Estrogen and related hormone effects Metabolism Diabetes and Cancer Adrenal Hormones and Disorders

Publication details

Journal / source
Fabad Journal of Pharmaceutical Sciences
Volume
51
Issue
1
Pages
419–434
Publication date
31 March 2026
Language
TR